WP00014_FriedlandFamily

An opportunity to support the
Peter Munk Cardiac Centre
In memory and honour of Sheldon Friedland

June 2017



Table of Contents

About the Peter Munk Cardiac Centre ................................................................................................................................ 3
World Firsts Happen Here ......................................................................................................................................................... 5
Areas of Care at the Peter Munk Cardiac Centre .......................................................................................................... 6
Opportunity for Impact: In memory and honour of Sheldon Friedland................................................. 8-15
Thank You ........................................................................................................................................................................................ 17
Appendix:
• Additional Recognition Options



About the Peter Munk Cardiac Centre

Thank you for your interest in supporting the Peter Munk Cardiac Centre, a global leader in
cardiovascular care, research and education.

The Peter Munk Cardiac Centre (PMCC) was established in1993 through the generous support
of Peter and Melanie Munk. Today, the PMCC has grown to over 162,000 out-patient visits a
year. Multidisciplinary surgical teams perform more than 2,000 cardiac and vascular surgeries,
over 7,800 interventional cardiology procedures, 35 heart transplants and 34 left ventricular
assist device or mechanical heart support implants a year, making the PMCC a high-volume
centre that cares for patients with the most complex cardiovascular disease in North America.

The PMCC is a technological state-of-the-art facility, deploying the latest diagnostic and
interventional techniques, bringing medical imaging, cardiology, cardiac surgery, and vascular
surgery together to lead in innovative multidisciplinary practice. Multi-slice CT scanners,
the latest MRI technology, and other imaging tools now produce sharper and more precise
images, diagnosing cardiac problems and supporting the development of less intrusive
treatments for our patients.

On the Canadian and international stage, the PMCC’s impact has been transformative —
much of it fueled by the generous contributions of grateful donors. These investments allow
the PMCC to continue the tradition of cardiovascular innovation that includes discoveries
that led to the development of the world’s first pacemaker, and the development of the
first coronary intensive care unit. The talent pool at the PMCC is enviable by any and all
international standards; many of the clinicians and scientists in the PMCC are counted among
the best in their field in the world.

Everything we do at the Peter Munk Cardiac Centre is based around how to make things
better for patients and for the healthcare system. Following are opportunities for support that
will ensure the Peter Munk Cardiac Centre remains at the forefront of revolutionizing heart and
vascular care for all of our patients and their families – here, and around the world.

I look forward to having the opportunity to further discuss your participation.

Yours truly,

Dr. Barry Rubin
Chair and Program Medical Director
Peter Munk Cardiac Centre

3

With a history of “firsts” and a spirit of innovation among its staff, patients and benefactors, the PMCC has
produced a legacy of breakthroughs in cardiovascular medicine. Its pioneering research is influencing
cardiovascular surgery across the world today.

World Firsts Happen Here

The Peter Munk Cardiac Centre is home to many world and Canadian firsts – discoveries
that translate to innovative care for cardiac patients. With a tradition of innovation, we
have the opportunity to redefine excellence in cardiovascular care worldwide through continued
and unprecedented technological breakthroughs.

Peter Munk Cardiac Centre world and Canadian Firsts

1935 1993

First clinical use of Heparin North America’s first cardiac operative
system, reducing intensive care stay by half
1950
The world’s first heart pacemaker 1996
The world’s first and only publicly available
1954 complete list of all human cardiovascular
The first use of hypothermia (cooling of genes
the body) for open heart surgery
1999
1955 Clinical trials of a new drug treatment
The first human heart valve transplant for heart failure and treatments for sleep
disorders
1962
The world’s first coronary intensive care 2001
unit First Canadian artificial heart

1986 2005

The first heart transplant in Canada First Canadian non-surgical percutaneous
mitral heart valve repair
1980
First prospective study of iliac angioplasty 2006
First discovery of the ‘SOS’ distress signal
1986
First stentless aortic valve 2007
First North American ‘bioresorbable’ heart
1988 defect implant
The development of the Toronto Heart
Valve, now used world-wide 2009
First heart monitor recorder – CARTO 3
1990 system
The world’s first genetic test for viral heart
disease 2012
First in Canada to successfully treat a patient
with uncontrolled hypertension

5

Areas of Care at the Peter Munk Cardiac Centre

The Peter Munk Cardiac Centre has six departments, each focusing on a distinct element of
cardiovascular care.

1. Adult Congenital Heart Disease

The PMCC’s Adult Congenital Heart Disease Program (ACHD) was the first program of its kind
to offer comprehensive care for adult survivors of congenital heart diseases and, after more
than 50 years, it is the largest program of its kind in the world, with more than 8,500 active
patients, more than 17,000 in its registry and about 750 referrals each year from across the
country. The ACHD outpatient clinic alone assessed 3,575 patients in 2016 and had more
than 4,600 outpatient visits. The number of outpatient visits is projected to approach 5,000 in
2020. Educational excellence is a hallmark of the PMCC, and the ACHD Fellowship Program
plays a critical role in the provision of ACHD education locally, nationally and internationally.
The Fellowship Program is one of the first of its kind and is the largest in the world. No other
program has trained more ACHD physicians over the last 20 years.

2. Coronary Artery Disease

Coronary artery disease is the most common form of heart disease and occurs when the
coronary arteries become narrowed by a build-up of fatty layers (also known as plaque) in
the artery walls. This process is called atherosclerosis, resulting in less blood flow reaching
the heart muscle, which causes pain and can lead to heart damage. The PMCC takes a multi-
faceted approach to address this global epidemic. Clinical specialists are performing and
developing new heart therapies, researchers are finding new ways to diagnosis heart disease,
and medical students and other healthcare professionals receive the latest education. With 17
different labs and clinics that touch directly or indirectly on coronary artery disease, the PMCC
looks at the condition from all angles.

3. Vascular Disease

The PMCC’s Division of Vascular Surgery is a world-class clinical care, research and academic
unit renowned for delivering care to patients with highly complex conditions through
advanced diagnostic and surgical interventions, including the use of minimally invasive,
percutaneous (through the skin) methods. One of the most significant developments in
recent years in the treatment of vascular diseases — conditions affecting the veins, arteries
and capillaries that carry oxygen-rich blood throughout the body such as aneurysms, blood
clots and ulcers — is the reduction in open surgery whereby large incisions are made in
the body. More than 90 per cent of the vascular-related procedures at the PMCC involving
balloons, stents and wires are now done with no incision at all.

6

4. Valvular Disease
The PMCC has received international recognition for its scientific contributions on the
diagnosis and treatment of patients with aortic and mitral valve diseases. Diseases of the
aortic and mitral valves are a leading cause of heart failure, yet the underlying causes and
molecular mechanisms of these diseases are not well understood. Known worldwide for its
pioneering valve-sparing root replacement procedure named for Dr. Tirone David, the valvular
disease team at PMCC continues to innovate. In August 2016, a multidisciplinary team at
the PMCC performed two successful tricuspid valve replacement procedures. The tricuspid
valve replacement procedure is very rare, with only about a dozen having been performed
worldwide since the method was established in early 2015.
5. Heart Failure/Heart Function
The Ted Rogers Centre of Excellence in Heart Function at the PMCC is the largest advanced
heart failure and heart transplant program in Canada. The Centre receives about 400 new
patient referrals and performs 2,600 follow-up visits each year for advanced therapies for
heart failure, including: transplantation, mechanical circulatory support, high-risk surgical
interventions, cardiac resynchronization therapy and optimization of medical therapy. The
team actively manages more than 2,000 patients with advanced heart failure, 320 heart
transplant recipients and 25 outpatient long-term mechanical circulatory supported patients.
The Centre has assessed about 4,000 new patients since 2000.
6. Heart Rhythm
The PMCC is an international leader in the investigation and treatment of heart rhythm
disorders. Electrical disorders of the heart or heart rhythm disorders are a major and
increasing cause of sudden cardiac death and disability in both young and aging populations.
Electrophysiology research staff is involved in ground breaking research aimed at improving
our understanding of and treatment of heart arrhythmias. Its specialists have already been
able to contribute to breakthroughs that have impacted treatments, diagnosis and care of
patients with electric disorders of the heart across Canada and around the world.

7

Opportunity for Impact:
In memory and honour of Sheldon Friedland

1. Peter Munk Cardiac Centre Fellowship Program
The Fellowship Program at the Peter Munk Cardiac Centre provides trainees from around the
world with the best clinical and research training in cardiology. This year alone the PMCC has
Fellows from Israel, Australia, Brazil, Argentina, England, the United States and Canada. Fellows
train as physician specialists through merging core competencies with specialized treatments,
including: cardiac resynchronization, mechanical circulatory support, electrophysiology,
transplantation, imaging and human physiology. Internationally recognized for its outstanding
physicians and its excellence in training, our goal is to develop Fellows into competent
practitioners.

Doctors in the Peter Munk Cardiac Centre share their insights with visiting Fellows from around
the world.
Opportunity for support
Our goal is to recruit the top talent in the world, which is why securing funding for Fellowships
is so crucial. There is no government funding to support these needs, and Fellowship
candidates are not eligible for student support. Generous donations from our patients and
their families have helped to fund these Fellowships.
There is an opportunity for the Friedland Family to honour Sheldon Friedland through the
naming of a Clinical Fellow MD for a period of two years at $85,000/yr. or a PhD Fellow in the
amount of $65,000/yr. for three years. Your support will help in training and establishing future
generations of specialists who will work tirelessly to fight heart disease.

8

Recognition Opportunities: Clinical or PhD Fellowship
Recognition may include:
• Naming of the Fellowship, for the term of the Fellowship
• Pewter recognition on Main Donor Walls at Toronto General Hospital and Toronto Western

Hospital
• Pewter recognition on Program Donor Wall(s), if applicable
• Donor’s name, or name of donor’s choice, to be used as part of Fellow’s title, stationery

and business cards, as well, papers published and activities carried out by the Fellow to
bear the name of the donor
• Pewter Upper Canada Medal
• Recognition Event with the Fellow
• Membership in Innovators’ Circle donor recognition society
• Meetings and/or Ongoing communication with the Fellow, including an annual written
Donor Impact Report

Global Impact in the Fellowship Program

Dr. James Lambert is an Echocardiography Fellow
from Perth, Australia. Donor support for the
Fellowship Program provides opportunities for
foreign physicians such as James to obtain highly
differentiated and specialized training.
The Echocardiography Laboratory is the busiest
in Canada, handling over 22,000 cases each
year. Fellows help screen and enroll patients in
clinical studies, attend procedures that require
echocardiographic guidance, collect and analyze
research data, and assist in writing research papers.
Doctors at the PMCC collaborate daily with Fellows
like James, sharing insights and innovations so that
every patient benefits from the experience of a cadre
of health professionals.

9

2. Peter Munk Cardiac Centre Professorship Program
Creating a Professorship is one of the most significant investments a donor can make at
the Peter Munk Cardiac Centre. A Professorship is an academic appointment held by an
established leader in a specific field who is a full time staff member of University Health
Network and holds the rank of Associate Professor or Professor at the University of Toronto.
Opportunity for support
A leadership investment of $500,000 (based on a five year commitment of $100,000/year) is
required to support a Limited Term Professorship at the Peter Munk Cardiac Centre in honour
of Sheldon Friedland. This expendable fund will provide the Professor with the resources to
conduct transformative work in research, patient care and teaching, while conferring prestige
to the holder and the institution.

Dr. R.J. Cusimano (left) is the holder of the David and Stacey Cynamon Professorship in
Cardiovascular Surgery Innovation & Education. Under his leadership, the PMCC is defining
best practices in research, education and clinical practice in cardiovascular surgical innovation.
Dr. Erwin Oechslin (right) is the Bitove Family Professor of Adult Congenital Heart Disease. As
Director of the Adult Congenital Heart Disease Program, Dr. Oechslin oversees the training of
more ACHD physicians than any other centre in the world.

10

Recognition Opportunities: Expendable Professorship at $500,000 over 5 years
Recognition may include:
• Naming of the Expendable Professorship, for the term of the Professorship
• Silver recognition on Main Donor Walls at Toronto General Hospital and Toronto Western

Hospital
• Silver recognition on Program Donor Wall(s), if applicable
• Donor’s name, or name of donor’s choice, to be used as part of Professor’s title and used

on Professor’s stationery and business cards. As well, papers published and activities
carried out by the Professor to bear the name of the donor
• Silver Upper Canada Medal
• Celebration Event with Professor to gather friends & family and honour Sheldon Friedland
• Framed Professorship Print (pictured)
• Membership in Innovators donor recognition society
• Meetings and/or Ongoing communication with Professor, including an annual written
Donor Impact Report

11

3. Peter Munk Cardiac Centre Chairs
A Chair is associated with the highest honour in academic life. It is an academic appointment
held by an established leader (scientist or clinician) in a specific field who is a full time staff
member of University Health Network and a full Professor at the University of Toronto. Chairs
are often used to attract and/or retain the stars of the Peter Munk Cardiac Centre. At present,
there are over twenty named Chairs at the Peter Munk Cardiac Centre.
Opportunity for support
With the support of the Friedland Family, and in honour of Sheldon Friedland, we are
pleased to offer the opportunity of a Limited Term Chair at $1,000,000 (based on a five year
commitment of $200,000/year). This expendable fund will be used to support the Chair holder
and offers him or her a predictable source of income to carry out and oversee important
research in his or her specialty.

Dr. Michael Gollob is the holder of the Peter Munk Chair in Cardiovascular Molecular Medicine.
Dr. Gollob leads a program in genomics at the Peter Munk Cardiac Centre that will help drive
precision medicine, identifying the best treatment for individual patients based on their genetic
makeup, and will also provide insight into a patient’s and family member’s risk of developing
heart disease.
12

Recognition Opportunities: Expendable Chair at $1,000,000 over 5 years
Recognition may include:

• Naming of the Expendable Chair, for the term of the Chair

• Gold Recognition on Main Donor Walls at Toronto General Hospital and Toronto Western
Hospital

• Gold Recognition on Program Donor Wall(s), if applicable

• Donor’s name, or name of donor’s choice, to be used as part of Chairholder’s title and used
on Chairholder’s stationery and business cards. As well, papers published and activities
carried out by the Chair to bear the name of the Donor

• Gold Upper Canada Medal

• Celebration Event with Chair to gather friends & family and honour Sheldon Friedland

• Framed Chair Print (pictured)

• Membership in Partners for Discovery donor recognition society

• Meetings and/or Ongoing communication with Chairholder, including an annual written
Donor Impact Report

Presented with profound appreciation to
The Family of Sheldon Friedland

on the occasion of the establishment of

Chair Name

This most generous endowment will create a legacy which will benefit
medicine and mankind for all time to come.
June 2017

______________________
Chair, University Health Network
______________________________
Chair, Toronto General & Western Hospital Foundation
______________________________
Chair, Governing Council University of Toronto

13



4. Support of a Peter Munk Cardiac Centre Clinical or Research Program
The fundamental goal of the Peter Munk Cardiac Centre is to conduct research that ultimately
leads to discovery, benefiting the health of the broader population. Named programs at the
PMCC support the efforts to grow, differentiate and impact cardiac care worldwide.
Named programs provide the opportunity for physicians to deliver leading-edge
cardiovascular care through a multidisciplinary, team-based approach. They establish the
PMCC as a unique centre that trains physicians in the delivery of multidisciplinary patient care,
a novel educational paradigm that does not adhere to the traditional boundaries associated
with individual specialties.
Opportunity for support
With an investment of $2 million (based on a ten year commitment of $200,000/year), we are
pleased to provide recognition of the program support at the Peter Munk Cardiac Centre in
honour of Sheldon Friedland aligned with your area of interest. This investment will lead to
a substantive change and improvement in the Canadian healthcare landscape, developing
processes to cultivate, support and manage innovation in patient care.
Recognition Opportunities: Naming a Program
• 3D, interior lettering may be displayed in area of support, if appropriate
• Example of existing lettering on adjacent page
• Gold Recognition on Main Donor Walls at Toronto General Hospital and Toronto Western

Hospital
• Gold Recognition on Program Donor Wall(s), if applicable
• Gold Upper Canada Medal
• Membership in Partners for Discovery donor recognition society
• Framed Partners for Discovery Print
• Celebration Event to gather friends & family and honour Sheldon Friedland

15



Thank You

To the Friedland Family:
Thank you for your consideration to support the Peter Munk Cardiac Centre. The excellence of
the Peter Munk Cardiac Centre stems from the generosity of donors like you, the calibre of our
researchers and the skill of our clinicians.
If you have any questions or would like further information, please contact:
Shauna Seabrook
Senior Campaign Director
Peter Munk Cardiac Centre Campaign
Toronto General & Western Hospital Foundation
University Health Network
T: 416-340-4945
E: [email protected]
petermunkcardiaccentre.ca

17



Appendix: Additional Recognition Options

Membership in Innovators’ Circle donor recognition society

Overview:
Launched in October 2011, the Innovators’ Circle seeks to acknowledge and involve donors
who have generously contributed between $100,000 and $999,999 to Toronto General Hospi-
tal and Toronto Western Hospital.
Through their incredible support, these donors have enabled us to continue our cutting edge
research, to provide superb patient centered care and to train and retain the best and the
brightest medical and scientific stars in the field.
Co-Chairs:
George Eaton, Board Member, TGWHF
Marvi Ricker, Board Member, TGWHF
Marvin Yontef, Board Member, TGWHF
Benefits Include:
• Invitation to annual Innovators’ Circle luncheon
• Bi-annual edition of Making the Rounds newsletter, which highlights information on re-

search breakthroughs, discoveries and other health-related topics at our hospitals
• Opportunities to arrange for private tours of Toronto General Hospital and/or Toronto

Western Hospital
• Invitation to bi-annual Behind the Scenes lecture
• Receipt of bi-annual Report on Your Support newsletter

20

Membership in Partners for Discovery donor recognition society

Overview:

Partners for Discovery is a special donor communications program, focused on supporters
who have made cumulative gifts of $1,000,000 or more to Toronto General & Western Hospital
Foundation.

As valued friends of our hospitals, we feel that the most meaningful way to thank these do-
nors for their generous support is to provide them with information on areas of health that are
of interest to them, in a timely and appropriate way.

Partners for Discovery now comprises a membership of over 233 donors, each of whom re-
ceives a special commemorative print.

Co-Chairs:

Anthony S. Fell, O.C., former Chairman of RBC Dominion Securities and Chair Emeritus, UHN
Trustees

Dr. Michael A. Baker CM, O. Ont, Past Physician-in-Chief, UHN

Benefits Include:

• Invitations to meet with President & CEO,
UHN, to learn about our latest develop-
ments and discoveries

• Invitation to our annual members’ dinner
at the Four Seasons Hotel

• The most up-to-date information on Dr. Peter Pisters, President and CEO of University Health Network
research breakthroughs, discoveries and with Her Royal Highness, The Princess Edward, Countess of Wessex
other health-related topics at our hospi- and Loretta Anne Rogers, Director, Toronto General and Western Hospital
tals including our bi-annual Insider’s Report Foundation at the annual members’ dinner
newsletter and various eblasts on late
breaking news stories

21

Partners for Discovery Commemorative Print

David & Elyssa Feldberg and Family

22

Celebration Event

We would be delighted to recognize your leadership and support by hosting a special cele-
bration in your honour. Appropriate leadership from the Toronto General and Western Hospi-
tal Foundation would be invited to attend this prestigious occasion, in addition to your family
and any guests you may wish to invite.

Upper Canada Medal

The Upper Canada Medal is presented to our donors at each of the levels of giving ($25,000+)
in gratitude for their generous support.

The Upper Canada Medal was originally created by the Loyal and Patriotic Society of Upper
Canada to provide recognition of distinguished service and bravery to volunteer soldiers in
the War of 1812.

Recognizing an even greater need, the Loyal and Patriotic Society decided to reduce the med-
als to gold bullion for the establishment in 1829, of the original Toronto General Hospital.

Toronto General & Western Hospital Foundation continues to honour both the original intent
of the medals, to recognize distinguished service and theFirrolantter role to support the greater
good.

Front Back

Cumulative Lifetime Giving Upper Canada Medal

$5,000,000+ Platinum
$1,000,000 - $4,999,999 Gold
Silver
$500,000 - $999,999 Bronze
$250,000 - $499,99B9ack Pewter
$100,000 - $249,999
$25,000 - $99,999 Copper

23

Recognition on the main Donor Walls at Toronto General Hospital and Toronto Western
Hospital for gifts of $25,000 or higher

McEwen Atrium, Toronto General Hospital
24

Main Hallway, East Wing, Toronto Western Hospital

25